Current advances of immunotherapy have greatly changed the way of cancer treatment.At the same time,a great number of nanoparticle-based cancer immunotherapies(NBCIs)have also been explored to elicit potent immune res...Current advances of immunotherapy have greatly changed the way of cancer treatment.At the same time,a great number of nanoparticle-based cancer immunotherapies(NBCIs)have also been explored to elicit potent immune responses against tumors.However,few NBCIs are nearly in the clinical trial which is mainly ascribed to a lack understanding of in vivo fate of nanoparticles(NPs)for cancer immunotherapy.NPs for cancer immunotherapy mainly target the immune organs or immune cells to enable effcient antitumor immune responses.The physicochemical properties of NPs including size,shape,elasticity and surface properties directly affect their interaction with immune systems as well as their in vivo fate and therapeutic effect.Hence,systematic analysis of the physicochemical properties and their effect on in vivo fate is urgently needed.In this review,we frst recapitulate the fundamentals for the in vivo fate of NBCIs including physio-anatomical features of lymphatic system and strategies to modulate immune responses.Moreover,we highlight the effect of physicochemical properties on their in vivo fate including lymph nodes(LNs)drainage,cellular uptake and intracellular transfer.Challenges and opportunities for rational design of NPs for cancer immunotherapy are also discussed in detail.展开更多
目的:探讨全胸腔镜下肺叶切除(VATS)联合系统淋巴清扫对肺癌患者血清疼痛相关因子和免疫功能的影响,并分析预后的影响因素。方法:选择我院于2014年3月~2016年3月期间收治的肺癌患者116例,采用随机数字表法分为对照组和研究组,各58例。...目的:探讨全胸腔镜下肺叶切除(VATS)联合系统淋巴清扫对肺癌患者血清疼痛相关因子和免疫功能的影响,并分析预后的影响因素。方法:选择我院于2014年3月~2016年3月期间收治的肺癌患者116例,采用随机数字表法分为对照组和研究组,各58例。对照组患者给予传统开胸肺叶切除联合系统淋巴清扫治疗,研究组给予VATS联合系统淋巴清扫治疗,对比两组手术相关指标、血清疼痛相关因子和免疫功能,随访记录研究组患者5年生存率,分析预后的影响因素。结果:与对照组相比,研究组手术时间更长,术中出血量更少,术后住院时间、切口长度、引流时间更短(P<0.05)。两组术后1 d去甲肾上腺素(NE)、前列腺素E2(PGE2)、P物质(SP)、皮质醇(Cor)水平均较术前升高,但研究组低于对照组(P<0.05)。两组术后1 d CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较术前降低,但研究组高于对照组,CD8^(+)较术前升高,但研究组低于对照组(P<0.05)。单因素分析结果可知:研究组患者的预后与组织分化、吸烟史、病灶直径、临床分期、清扫淋巴结个数有关(P<0.05)。多因素Logistic回归分析结果可知:临床分期、清扫淋巴结个数是研究组患者预后的影响因素(P<0.05)。结论:VATS联合系统淋巴清扫可减轻肺癌患者术后疼痛及免疫抑制,虽然手术时间更长,但可以改善其他围术期指标。此外,临床分期、清扫淋巴结个数是患者预后的影响因素,应引起临床重视。展开更多
基金supported by National Key Research&Development Program of China(Grant No.2018YFE0117800,China)the National Natural Science Foundation of China(NSFC)key projects(grant No.31630027,32030060,51773227 and 81701815,China)+3 种基金NSFC international collaboration key project(Grant No.51861135103,China)NSFC-German Research Foundation(DFG)project(Grant No.31761133013,China)appreciate the support by“the Beijing-Tianjin-Hebei Basic Research Cooperation Project”(19JCZDJC64100,China)the Youth Thousand-Talents Program of China。
文摘Current advances of immunotherapy have greatly changed the way of cancer treatment.At the same time,a great number of nanoparticle-based cancer immunotherapies(NBCIs)have also been explored to elicit potent immune responses against tumors.However,few NBCIs are nearly in the clinical trial which is mainly ascribed to a lack understanding of in vivo fate of nanoparticles(NPs)for cancer immunotherapy.NPs for cancer immunotherapy mainly target the immune organs or immune cells to enable effcient antitumor immune responses.The physicochemical properties of NPs including size,shape,elasticity and surface properties directly affect their interaction with immune systems as well as their in vivo fate and therapeutic effect.Hence,systematic analysis of the physicochemical properties and their effect on in vivo fate is urgently needed.In this review,we frst recapitulate the fundamentals for the in vivo fate of NBCIs including physio-anatomical features of lymphatic system and strategies to modulate immune responses.Moreover,we highlight the effect of physicochemical properties on their in vivo fate including lymph nodes(LNs)drainage,cellular uptake and intracellular transfer.Challenges and opportunities for rational design of NPs for cancer immunotherapy are also discussed in detail.
文摘目的:探讨全胸腔镜下肺叶切除(VATS)联合系统淋巴清扫对肺癌患者血清疼痛相关因子和免疫功能的影响,并分析预后的影响因素。方法:选择我院于2014年3月~2016年3月期间收治的肺癌患者116例,采用随机数字表法分为对照组和研究组,各58例。对照组患者给予传统开胸肺叶切除联合系统淋巴清扫治疗,研究组给予VATS联合系统淋巴清扫治疗,对比两组手术相关指标、血清疼痛相关因子和免疫功能,随访记录研究组患者5年生存率,分析预后的影响因素。结果:与对照组相比,研究组手术时间更长,术中出血量更少,术后住院时间、切口长度、引流时间更短(P<0.05)。两组术后1 d去甲肾上腺素(NE)、前列腺素E2(PGE2)、P物质(SP)、皮质醇(Cor)水平均较术前升高,但研究组低于对照组(P<0.05)。两组术后1 d CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较术前降低,但研究组高于对照组,CD8^(+)较术前升高,但研究组低于对照组(P<0.05)。单因素分析结果可知:研究组患者的预后与组织分化、吸烟史、病灶直径、临床分期、清扫淋巴结个数有关(P<0.05)。多因素Logistic回归分析结果可知:临床分期、清扫淋巴结个数是研究组患者预后的影响因素(P<0.05)。结论:VATS联合系统淋巴清扫可减轻肺癌患者术后疼痛及免疫抑制,虽然手术时间更长,但可以改善其他围术期指标。此外,临床分期、清扫淋巴结个数是患者预后的影响因素,应引起临床重视。
